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ABSTRACT
Activin A (ActA)/follistatin (FST) signaling has been shown to be deregulated 
in different tumor types including lung adenocarcinoma (LADC). Here, we report 
that serum ActA protein levels are significantly elevated in LADC patients (n=64) 
as compared to controls (n=46, p=0.015). ActA levels also correlated with more 
advanced disease stage (p<0.0001) and T (p=0.0035) and N (p=0.0002) factors. M1 
patients had significantly higher ActA levels than M0 patients (p<0.001). High serum 
ActA level was associated with poor overall survival (p<0.0001) and was confirmed 
as an independent prognostic factor (p=0.004). Serum FST levels were increased 
only in female LADC patients (vs. female controls, p=0.031). Two out of five LADC 
cell lines secreted biologically active ActA, while FST was produced in all of them. 
Transcripts of both type I and II ActA receptors were detected in all five LADC cell 
lines. In conclusion, our study does not only suggest that measuring blood ActA levels 
in LADC patients might improve the prediction of prognosis, but also indicates that 
this parameter might be a novel non-invasive biomarker for identifying LADC patients 
with organ metastases.
INTRODUCTION
Approximately 40 % of lung cancer patients have 
lung adenocarcinoma (LADC, a subtype of non-small cell 
lung cancers (NSCLCs). Because there are differences 
with respect to prognoses between patients with the 
same stage, there is an urgent need to identify clinically 
useful non-invasive biomarkers that provide additional 
prognostic information to improve therapeutic decision-
making and prediction of prognosis in this malignancy. 
There are only a few blood-based biomarkers currently 
investigated in LADC. Protein markers, for instance 
serum cytokeratin 19 fragments (CYFRA 21-1), have 
been investigated recently in patients with advanced 
LADC [1]. Other examples are carcinoembryonic antigen 
(CEA) [2], serum amyloid A (SAA) [3, 4], cancer antigen 
125 (CA 125) [2, 5], haptoglobin-alpha 2 (HAP2) [6, 7], 
apolipoprotein A1 (ApoA1) [6, 8], kallikreins (KLKs) 
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[9-11], laminin C2 (lamC2) [5] and plasma fibrinogen 
[12]. The analysis of other circulating tumor-derived 
biomarkers like cell-free nucleic acids (such as DNA and 
microRNAs [13]), metabolites [14, 15] or circulating 
tumor cells (CTCs) [13, 16, 17] might also hold potential 
in predicting clinical outcome. However, taken together, 
the evidence for the prognostic significance of the above 
mentioned biomarkers is still rather modest [18].
Activin A (ActA), a member of the TGF-beta 
superfamily of cytokines, is formed via the covalent 
intracellular dimerization of two inhibin ßA (IHNBA) 
subunits [19]. ActA first binds to the type II activin 
receptors (ActR-IIA or ActR-IIB) on the cell surface, 
leading to the recruitment and phosphorylation of the 
type I activin receptor ActR-IB [20]. Receptor-regulated 
SMADs (R-SMADs) 2 and 3 are recruited to the receptor 
complex and phosphorylated by the type I receptor, 
which allows them to form complexes with SMAD4 and 
translocate to the nucleus where they are involved in the 
regulation of gene expression [20]. ActA is involved in a 
variety of biological functions including control of cellular 
differentiation, homeostasis of cell number and tissue 
architecture in multiple organs [21]. Follistatin (FST) is 
the natural antagonist of ActA, binding with high affinity 
to its ß subunit and preventing its interaction with the type 
II activin receptors [22]. The ActA/FST complex is then 
mainly internalized and degraded in the lysosomes [23].
Deregulated expression of - or mutations in - 
components of the activin signaling axis have been 
found in a broad range of malignancies. In cancer of 
the breast, liver and colon, activin signals were found 
to inhibit tumor cell growth and tumor tissue expressed 
decreased levels of ActA, increased levels of activin 
antagonists or demonstrated a loss of functional activin 
receptors or SMAD proteins [24-27]. In contrast, in oral 
squamous cell carcinoma (OSCC), esophageal ADC and 
malignant pleural mesothelioma, high ActA expression 
increased tumor cell aggressiveness [28-33]. The two 
studies that investigated the expression of ActA in clinical 
LADC samples yielded conflicting data. In the first 
study, overexpression of ActA in LADC tissue showed 
association with poor prognosis in stage I patients [34]. 
In the second study, decreased expression of ActA in the 
tumor tissue and a negative correlation of ActA protein 
level with lymph node (LN) metastasis was reported [35].
Overexpression of FST has been found in 
melanoma, prostate cancer and hepatocellular carcinoma 
[27, 36, 37]. Chen et al reported that FST serum levels of 
LADC patients are elevated and that this parameter might 
be a useful biomarker for the diagnosis of LADC [38]. In 
a preclinical model of SCLC, however, FST inhibited the 
formation of multiple organ metastases [39].
Because there has been no detailed analysis of 
circulating ActA and FST levels - and of their potential 
correlation - in LADC, we investigated the expressions of 
the members of the ActA/FST signaling system in LADC 
cell lines and, moreover, assessed plasma and serum 
levels of ActA/FST and correlated them with the patients’ 
clinicopathological parameters and survival.
RESULTS
Testing of activin A and follistatin ELISA assays
To test whether ActA/FST complexes interfere with 
the ELISA detection of ActA and/or FST alone, FST and 
ActA levels of plasma samples were determined after 
treatment either with recombinant human (rh)ActA or 
rhFST, respectively. No significant differences could be 
detected between ActA concentrations of the untreated 
plasma and the samples incubated with rhFST at different 
concentrations (2, 5, 100 ng/ml), demonstrating that the 
ActA ELISA detects both free (active) and FST-bound 
(inactive) ActA (Supplemental Figure 1A). In contrast, 
treatment of plasma with 50 and 100 ng/ml rhActA 
decreased the levels of measurable FST, indicating that 
only free (and not the ActA-bound form of) FST can be 
detected by the ELISA kit (Supplemental Figure 1B). 
Circulating ActA levels are elevated in LADC 
patients in a stage-dependent manner
ActA level was measured in serum samples of 64 
LADC patients and 46 age- and gender-matched controls 
and in plasma samples of 87 LADC patients and 66 age- 
and gender-matched control individuals (Supplemental 
Table 1). In the control group, the mean values of ActA 
serum and plasma concentrations were 457.2±119.6 pg/
ml and 344.0±142.4 pg/ml, respectively (Figure 1A and 
Supplemental Figure 2A). In patients with LADC, these 
concentrations were significantly higher, with a mean 
serum value of 650.0±365.3 pg/ml and a mean plasma 
value of 561.6±500.5 pg/ml (p = 0.015 and p < 0.0001, 
respectively; Figure 1A and Supplemental Figure 2A). 
In the case of 58 patients where ActA levels were 
determined in both plasma and serum samples, serum 
levels were significantly higher, with a mean value of 
640.9±371.9 (vs. 461.4±257.2, p = 0.006, data not shown). 
Importantly, however, we found a strong correlation 
between plasma and serum ActA levels in this patient sub-
cohort (Supplemental Figure 2B, R = 0.932, p < 0.0001). 
The clinicopathological characteristics of the patients 
with high and low ActA serum or plasma concentrations 
(dichotomized by the median) are presented in Table 1 and 
Supplemental Table 2, respectively. Blood ActA levels 
and disease stage showed significant positive correlations. 
However, no significant associations of circulating ActA 
levels with gender, age, therapy or smoking status were 
detected. We found no significant differences between 
ActA levels (serum or plasma) of never-, ex-, and current 
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Table 1: Clinicopathological characteristics of patients grouped by serum ActA level





Characteristics Numbers (%) Numbers (%) p-value* Numbers (%)
Gender
Male 14 39 22 61 0.044 36 56Female 18 64 10 36 28 44
Age (years)       
< 62 18 62 11 38 0.079 29 45
≥ 62 14 40 21 60 35 55
Smoking**  
ever smoker 27 47 31 53 0.15 58 91never smoker 4 80 1 20 5 8
Stage       
I-II 17 77 5 23
0.003
22 34
III 9 47 10 53 19 30
IV 6 26 17 74 23 36
Treatments  
C(R)T*** 11 33 22 67
0.028
33 51
S 3 100 0 0 3 5
S+C(R)T 5 71 2 29 7 11
PT 13 62 8 38 21 33
* two-sided χ2 test; **in case of one patient data were not available; ***9 patients re-
ceived targeted therapy
Abbreviations: C(R)T=chemo- and/or radiotherapy; S=surgery; S+C(R)T=surgery and chemo- 
and/or radiotherapy; PT=palliative treatment
Figure 1: Serum ActA levels are elevated in patients with LADC and correlate with tumor progression. A. ActA 
concentration is significantly higher in the serum samples of patients with LADC (p = 0.015, vs. controls). B., C., D. T and N status- and 
stage-dependent increase of serum ActA in LADC (*p < 0.05, **p < 0.01, ***p < 0.001). 
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smokers (data not shown).
The ROC curve analysis showed a sensitivity 
of 60.9% (95% CI: 47.93-72.90 %) and a specificity 
of 65.2% (95 % CI: 49.8-78.7 %) of serum and 66.7 % 
sensitivity (95 % CI: 53.9-77.8 %) and 62.1% specificity 
(95% CI: 51.0-72.3%) of plasma ActA levels for correct 
diagnosis of LADC (data not shown). The area under 
the curve (AUC) values were 0.637 (95 % CI: 0.534 to 
0.741) in serum and 0.685 (95% CI: 0.6014-0.7682) in 
plasma (data not shown). We also observed a stage- and 
T and N status-dependent increase of circulating ActA 
concentrations (Figure 1B-1D, Supplemental Figure 2C-
2E). Serum ActA levels were significantly elevated in 
stage IV patients as compared to controls or to patients 
with any earlier stage of the disease (Figure 1B). In 
line with this, stage IV LADC patients had significantly 
higher plasma ActA levels than controls or those with 
stage I-II disease (Supplemental Figure 2C). ActA levels 
were also significantly increased in both the serum (vs. 
control and T1 cases; Figure 1C) and in the plasma (vs. 
control; Supplemental Figure 2D) of T3 LADC patients. 
Furthermore, higher circulating serum (Figure 1D) and 
plasma (Supplemental Figure 2E) ActA levels were 
associated with increased LN metastasis. For detailed 
ActA serum and plasma concentrations of the patient and 
control cohorts, please refer to Supporting information 
(Supplemental Table 3). 
High circulating ActA associates with organ 
metastasis, has diagnostic significance and 
correlates with poor overall survival in LADC
Both serum (Figure 2A) and plasma (Supplemental 
Figure 2F) ActA levels were significantly increased 
in patients with metastatic disease as compared to M0 
patients (p < 0.001 in both cases). ROC curve analysis 
revealed that serum ActA had a sensitivity of 82.6% (95% 
CI: 61.2-95.1%) and a specificity of 63.4 %, (95 % CI: 
46.9-77.9 %) to differentiate metastatic patients from M0 
cases (Figure 2B). In plasma, the sensitivity was 70.3% 
(95% CI: 53.0-84.1%) with a specificity of 68.0% (95% 
CI: 53.3-80.5%; Supplemental Figure 2G). The AUC was 
0.806 (95% CI: 0.693- 0.919) in serum (Figure 2B) and 
0.743 (95% CI: 0.634-0.852 %) in plasma (Supplemental 
Figure 2G). 
Because LN and organ metastatic LADCs were 
characterized by a significant increase in circulating ActA 
levels, we next used Kaplan-Meier analysis to calculate 
the overall survival (OS) rate for patients with low and 
high serum (Figure 3) or plasma ActA (Supplemental 
Figure 3) levels. These classifications were based on 
the median values of ActA concentrations in our patient 
population. We found that LADC patients with high 
serum or plasma ActA levels had significantly shorter OSs 
than those with low circulating ActA concentrations (p < 
0.0001, in the cases of both comparisons, Figure 3A and 
Supplemental Figure 3A). If we classified the patients 
according to their disease stage, low serum ActA levels 
were still significantly associated with benefit in OS in 
the stage I-II sub-cohort (p = 0.0047; Figure 3B) while a 
trend towards longer OS for patients with low ActA serum 
levels in the stage III and IV sub-cohorts did not reach 
significance (Figure 3B). Accordingly, stage I-II or stage 
IV patients with low plasma ActA levels had significantly 
better OS than the corresponding cases in the high plasma 
ActA level arms (p = 0.0004 and p = 0.0465, respectively, 
Supplemental Figure 3B). Of note, stage III patients with 
low ActA plasma levels also tended to have better survival 
(Supplemental Figure 3B). 
Multivariate analysis (including standard prognostic 
parameters such as patient age, gender and tumor stage) 
also showed that serum and plasma ActA concentrations 
predicted outcome independent of other variables (p = 
0.004 and 0.002, respectively; Table 2 and Supplemental 
Table 5). Further prognostic factor related to OS was 
disease stage in the ActA plasma cohort (p = 0.012). 
Table 2: Cox regression model adjusted for patient characteristics of all cases (n=64)
Serum ActA level
Characteristics Adjusted HR for death 95% CI
Adjusted 
p-value
Age, years   
0.807<62 0.918 0.460-1.828
≥62 1  
Gender   
0.115Female 1  
Male 1.775 0.869-3.625
Stage   0.130
Serum ActA level   
0.004Low ActA 1  
High ActA 4.142 1.583-10.837
Abbreviations: HR, hazard ratio; CI, confidence interval
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Figure 2: A. Serum ActA concentration is elevated in patients with M1 disease (***p < 0.001). B. Serum ActA is a useful biomarker for 
the identification of organ metastatic LADC: AUC: 0.806 (95% CI: 0.693 to 0.919). 
Figure 3: Kaplan-Meier curves for OS of LADC patients according to serum ActA level (cut-off value is the median). 
A. LADC patients with high serum ActA levels had significantly shorter OS than those with low serum ActA levels (median OS was 7.9 vs. 
39.6 months, HR: 0.2768, 95% CI 0.1450 to 0.5286; p < 0.0001). B. Low serum ActA was associated with a significant OS benefit in the 
subgroup of early-stage (I-II) cases (median OS was undefined vs. 6.4 months, HR: 0.05945, CI: 0.008380-0.4217, p = 0.0047). There was 
a tendency for longer OS in the high ActA group in stage III patients (median OS: 39.6 vs. 22.4 months, HR: 0.5349, CI: 0.1628-1.757) and 
in stage IV patients (median OS: 8.3 vs. 5.9 months, HR: 0.6951, CI: 0.2700-1.789).
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Serum FST level is elevated only in female LADC 
patients
Since the activity of circulating ActA is regulated by 
its bounding to FST, serum samples of 64 LADC patients 
and 46 age- and sex-matched controls were also analyzed 
for FST concentrations. There was no difference in the 
FST serum levels between controls and LADC patients 
(1685±536.1 pg/ml vs. 1912±1227 pg/ml, respectively, 
p = 0.621; Supplemental Figure 4A). When a separate 
analysis of males and females was conducted, we found 
similar serum FST levels in the male and female controls 
as well as in the male LADC patients (1766±578.9 pg/
ml, 1623±503.6 pg/ml 1650±670.9 pg/ml, respectively). 
However, we detected significantly increased serum FST 
concentrations in female LADC patients (2249±1649 pg/
ml, p = 0.031, vs. female controls, Supplemental Figure 
4B). 
There was no association between FST levels and 
ActA concentrations, TNM stage or OS (data not shown). 
Serum FST had no diagnostic value in the full cohort. 
In females, the sensitivity was 60.7% (95% CI: 40.5-
78.5%) and the specificity was 61.5% (95% CI: 40.6-
79.8%) with an AUC of 0.672 (95% CI: 0.5271-0.8163). 
No significant differences between ActA/FST ratios of 
controls and LADC patients were observed and there was 
no correlation between ActA/FST ratios and TNM stage or 
clinical outcome (data not shown).
ActA, FST and activin receptors are expressed in 
LADC cell lines
We analyzed the in vitro ActA and FST secretions 
of five different LADC cell lines by ELISA. ActA was 
detectable in the supernatants (SNs) of 3 cell lines (H1650, 
HCC827, H358). In two of these cell lines (H1650, 
Figure 4: Expression of the members of the ActA/FST system in LADC cell lines. A. LADC cells were incubated for 24 hours 
in serum-free medium and ActA levels of the SNs were determined by ELISA. ActA was detected in the SN of three of five LADC cell lines. 
B. LADC cell SNs were obtained as described above and FST levels were determined by ELISA. High levels of FST were found in all five 
LADC cell SNs. C. Phosphorylation of SMAD2 in HepG2 cells treated with SNs of LADC cell lines. SNs of LADC cells were prepared 
as described above. HepG2 cells were treated with SNs or medium with or without recombinant ActA (0.5 ng/ml) for 30 min. Cells were 
then harvested, and phosphorylation of SMAD2 was measured by Western blot analysis, using beta-actin as loading control. SMAD2 was 
phosphorylated upon treatment with the SN of H1650 and H358 cells, showing that ActA produced by these cell lines has biologic activity. 
D. Expression of activin receptors in LADC cell lines, measured by QPCR, using GAPDH as reference for normalization. The transcripts 
of ActR-1B, 2A and 2B were detected in all five cell models.
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HCC827), we found relatively low ActA concentrations 
(22.4 and 22.1 pg/ml, respectively), while H358 cells 
produced and secreted high amounts of the protein (530.6 
pg/ml; Figure 4A). In the case of FST, all five cell lines 
secreted the protein: the concentrations varied between 
151.6 pg/ml (H1975) and 624.8 pg/ml (A549) (Figure 4B). 
It has been demonstrated previously that HepG2 
hepatoma cells are responsive to ActA: In these 
cells, treatment with exogenous rhActA leads to the 
phosphorylation of SMAD2, and this assay is thus suitable 
to measure the activity of ActA [26]. When HepG2 cells 
were treated with conditioned SNs of the five different 
LADC cell lines, phosphorylation of SMAD2 was induced 
in two of the cell models (H1650, H358; Figure 4C).
We also measured the mRNA levels of activin 
receptors in five LADC cell lines by QPCR. Each cell line 
expressed the type II receptors ActR-IIA and ActR-II, as 
well as the type I receptor ActR-IB (Figure 4D).
DISCUSSION
Although a number of blood markers have been 
reported to predict prognosis in NSCLC, the results of 
these studies are heterogeneous [1-18]. To our knowledge, 
this is the first study to link elevated blood levels of ActA 
to disease progression and adverse outcome in LADC.
Depending on the tumor type, ActA can play a pro-, 
as well as an anti-tumor role. In breast, liver and colon 
cancer, ActA inhibits tumor growth [25-27]. Some other 
tumors, however, gain resistance to the growth-inhibitory 
effect of ActA. In these malignancies, ActA can even 
stimulate tumor cell proliferation and aggressiveness [29, 
34].
The two studies that investigated the expression 
of ActA in LADC tissues delivered conflicting data. On 
the one hand, Shan et al. demonstrated that ActA protein 
levels are decreased in LADC samples and that low ActA 
expression correlates with more advanced disease stages 
[35]. On the other hand, Seder et al. reported mRNA and 
protein overexpression and a negative prognostic role 
of ActA in stage I LADC tissue [34]. Our current study 
reveals ActA as a novel circulating prognostic biomarker 
in LADC. It also provides the first evidence for a direct 
association of blood ActA concentrations and primary 
tumor size and LN metastasis in any human malignancy.
We demonstrate a strong association between 
circulating ActA levels and the T factor of primary 
LADCs. Our finding is supported by other studies on 
breast, endometrial, cervical and oral cancer [40-42] in 
which the major source of elevated circulating ActA was 
speculated to be the primary tumor tissue. It is important 
to mention that Seder et al. observed immunoreactivity in 
only 78 % of primary LADC samples [34], and that we 
found detectable ActA secretion only in three out of our 
five LADC cell lines. In addition to the cancer cells, other 
cell types in the tumor microenvironment such as cancer-
associated fibroblasts [42] and neutrophils [43] could also 
contribute to the ActA production of the primary tumors.
When discussing the regulation of circulating 
ActA levels, the naturally produced activin-binding 
protein FST [44], must also be taken into account. In 
melanoma, prostate and hepatocellular carcinoma, a 
mechanism underlying the resistance to the growth 
inhibitory effect of ActA is FST overexpression [27, 36, 
37]. Primary LADC cells express FST, and patients with 
this malignancy have elevated serum FST levels [38, 45]. 
Although FST was demonstrated to protect LADC cells 
from ActA-induced-apoptosis in vitro [38], others have 
shown an anti-proliferative effect of FST on LADC cells 
[34]. Here, we confirmed that LADC cells secrete FST in 
vitro. Interestingly, this was reflected by increased blood 
FST concentrations only in female patients. However, we 
found that the ELISA kit we used detects only the free 
form of FST (and not the ActA-bound). Of note, secretion 
of other binding partners of FST (e.g. bone morphogenetic 
proteins [46] or angiogenin [47]) may also influence the 
concentration of free FST in the blood.
With an assay measuring the phosphorylation 
of SMAD2 in HepG2 cells, we could also prove that 
- despite their high FST expressions - LADC cells 
secrete biologically active ActA protein. Besides FST 
overexpression, loss of activin receptor expression [24] 
is another mechanism to gain resistance to ActA. Our 
LADC cell lines expressed both type I and II activin 
receptors, suggesting that this is not the case in this tumor 
type. Other mechanisms (e.g. loss of SMAD4 or of the 
tumor suppressor p15INK4B) could also be involved in 
the resistance to the anti-tumor effect of ActA, as it was 
shown in other types of cancer [26, 48].
As for the role of ActA in lymphatic tumor spread, 
an earlier study on circulating ActA levels in breast cancer 
failed to show a correlation with N status, whereas in 
OSCC and esophageal carcinoma the presence of LN 
metastases was associated with elevated tumor tissue ActA 
expression [31, 49]. In a recent study from our group, 
in which the gene expression profile of tumorous and 
normal mediastinal LN samples of NSCLC patients were 
evaluated by microarray analysis, INHBA (the subunit of 
ActA), was one of the most highly up-regulated genes in 
metastatic LNs [50]. However, we also identified ActA as 
a potent anti-lymphangiogenic factor [51]. Nevertheless, 
in the same experimental study, ActA did not have an 
impact on the LN metastatic capacity of melanoma cells 
[51], suggesting that the net effect of ActA signaling on 
lymphatic tumor dissemination is not straightforward and 
that these controversial results warrant additional research.
Although a circulating factor that predicts the 
organ metastatic capacity of lung cancer would be of 
paramount clinical significance, we believe that no such 
blood biomarker has been described so far. A striking 
finding from this study is, therefore, that LADC patients 
with organ metastases had significantly higher blood ActA 
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levels than those with M0 disease. Whether these elevated 
ActA levels are a cause or consequence of the metastatic 
dissemination remains to be elucidated. Nevertheless, our 
findings are supported by previous studies on breast and 
prostate cancer where elevated circulating ActA levels 
were associated with the presence of bone metastases [52, 
53]. Overexpression of FST inhibited the organ metastasis 
of SCLC in vivo [39], further corroborating the role of 
ActA in the metastatic process. 
In conclusion, our study, for the first time, 
demonstrates that blood ActA levels are elevated in LADC 
patients. Moreover, circulating ActA concentration at the 
time of diagnosis is an independent prognostic marker in 
this malignancy. Importantly, our data also suggest that 
both serum and plasma ActA are useful biomarkers for 
identifying LADC patients with organ metastatic disease. 
Although further independent and prospective studies 
are needed to fully explore the prognostic and diagnostic 
potential of the ActA/FST system in LADC, inhibitors of 
activin signaling are already being evaluated in clinical 
trials, highlighting the significance of this system in 
patients with malignant tumors.
PATIENTS AND METHODS
Patients
In a combined cohort from two institutions (Division 
of Thoracic Surgery, Medical University of Vienna (n 
= 25) and National Koranyi Institute of Pulmonology, 
Budapest (n = 68)), plasma and serum samples of patients 
with LADC were collected between 2011 and 2014 at the 
time of diagnosis or before surgical resection. Additional 
samples from healthy individuals and patients with COPD, 
diabetes mellitus, cardiovascular disease (CVD), asthma 
and liver disease (that, as described in refs. [54-58], 
might also influence circulating ActA/FST levels) were 
also analyzed. Numbers of patients included in the study 
are summarized in Supplemental Table 1. All patients 
and controls had given informed consent and the sample 
collection was approved by the Ethics Committees of 
the Medical University of Vienna (#904/2009) and the 
National Koranyi Institute of Pulmonology (2521-0 2010-
1018EKU).
Collection of blood
Samples from LADC patients and controls were 
prepared from approximately 10 ml blood collected with 
EDTA vaccutainers for plasma or with BD vacutainer 
serum separator tube (#367985) or clot activator tube 
(#368815) for serum. Blood samples were centrifuged, 
aliquoted and stored at -80 °C until use as described in 
ref. . [59]. 
ELISA assays
Quantikine ActA and FST ELISAs were purchased 
from the R&D Systems (DAC00B and DFN00, 
respectively). Sample preparation, standard curve 
generation and measurement of samples in duplicates were 
performed according to the guidelines of the manufacturer.
Cell lines
The H1975, H358, HCC827, A549 and H1650 
LADC cell lines were obtained from the American Type 
Culture Collection (Manassas, VA). All cell lines were 
cultured in RPMI-1640 (Sigma Chemical Co., St. Louis, 
MO) supplemented with 10% fetal bovine serum (FBS, 
Sigma) and 100 U/ml penicillin-100 Ag/ml streptomycin 
(Sigma). HepG2 hepatoma cells were cultured in MEM 
supplemented with 1 mM sodium pyruvate, 1% non-
essential amino acids and 10% FBS). All cell lines were 
maintained at 37°C in a humidified incubator with 5% 
CO2.
Preparation of cell supernatants for ELISA and 
bioactivity assay
For ELISA measurements, LADC cell line 
supernatants (SNs) were obtained from T25 flasks with 
1.5x106 cells after 24 hours incubation with 2 ml cell 
culture media without FBS. After centrifugation (800 rpm, 
5 min, 24°C), aliquots were stored at -80°C until analysis.
Expression of activin receptors in LADC cell lines
Isolation of total RNA, cDNA synthesis and 
measurement of ACVR1B, ACVR2A, ACVR2B were 
performed as described previously [33]. Briefly, total RNA 
was isolated from LADC cells. 2µg RNA was reverse 
transcribed with MMLV reverse transcriptase (Thermo 
Scientific, Waltham, MA, USA). Quantitative real-time 
PCR (QPCR) was performed with SYBR Green (Life 
Technologies), as previously described [33], using an ABI 
Prism 7500 Fast SDS thermocycler (Life Technologies) 
and primers for ACVR1B (for: 5’-GCC CTC TGA CCC 
TTC CAT TG-3’; rev: 5’-CCC GCA GTG CCT CAT AAC 
TC-3’), ACVR2A (for: 5’-ACC CAG ATG CAG AGA 
CTA AC-3’; rev: 5’-ATG GCG CAA CCA TCA TAG 
AC-3’), ACVR2B for: 5’-TCA GCA CAC CTG GCA 
TGA AG-3’; rev: 5’-TCA TGG AAG GCC GTG ATG 
AG-3’) and GAPDH (for: 5’-agctcactggcatggccttc-3’; 
rev: 5’-acgcctgcttcaccaccttc-3’). GAPDH was used as 
reference for normalization and relative mRNA expression 
was calculated as 2(−ΔCT x 104). 
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ActA bioactivity assay
5x105 LADC cells were seeded in 2 ml cell culture 
medium in a six-well plate. Next day, SNs were collected. 
5x105 HepG2 cells, seeded in a six-well plate, were 
washed with phosphate buffered saline and treated with 
0.5 ml LADC supernatant or 0.5 ml growth medium with 
or without 0.5 ng/ml rhActA (R&D Systems, 338-AC). 
After 30 min incubation at 37°C, cells were harvested in 
lysis buffer. 20 µg protein were separated by SDS-Page, 
blotted onto PVDF membranes and blocked in 5% skim 
milk in TBST as published earlier [33]. Membranes 
were incubated overnight at 4°C with primary antibodies 
(p-SMAD2, Cell Signaling, #3101; total SMAD2, Cell 
Signaling, #5339, dilution 1:1000 and beta-actin, Sigma, 
A5441, dilution 1:5000). Horseradish peroxidase-coupled 
anti-rabbit/mouse antibodies (3% BSA, Dako) were used 
at 1:10 000 dilutions and developed with Clarity Western 
ECL reagent (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Cut-off level for high and low ActA was set by the 
median. To determine statistical differences between two 
groups, t-test was applied. ANOVA was used with the 
post hoc Dunn-test for the comparison of more than two 
groups. Categorical data were compared using Fishers’ 
exact probability and chi-square tests. OS intervals were 
determined as the time period from initial diagnosis to the 
time of death. Kaplan-Meier curves for OS were evaluated 
for all patients in the study and the log-rank test was used 
to establish the significance of the difference. Multivariate 
analysis of the clinical parameters was performed using 
the Cox regression model. P values are given as two-sided 
and were considered statistically significant below 0.05. 
All statistical analyses were performed using the PASW 
Statistics 18.0 package (Predictive Analytics Software, 
SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0 
(GraphPad Inc., San Diego, CA).
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